Standard Alzheimer’s Treatments Seen to Prevent Effects of TauRx’s Tau Inhibitor

Standard Alzheimer’s Treatments Seen to Prevent Effects of TauRx’s Tau Inhibitor
TauRx Therapeutics’ experimental Alzheimer’s disease treatment LMTX may slow cognitive decline in patients at doses as low as 4 mg — but only when used without other Alzheimer’s drugs — a recent report shows. The findings support data from an earlier Phase 3 trial, which also studied much higher doses of the drug, and have opened

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Zachary Yim says:

    Surprising to see the effect of Tau dis-aggregation can result in higher glucose uptake. Does it mean insulin resistance is downstream of Tau pathology? Other animal models seems to show the opposite situation. Does it also mean this treatment would eliminate the need for intranasal insulin?

    • Ari Magill says:

      Seems to me like intranasal insulin would bolster the effect, a combined approach might be best. I’m very curious how Acetylcholinesterase inhibitors negate the beneficial effect of tau aggregation inhibitors

Leave a Comment

Your email address will not be published. Required fields are marked *